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Abstract
Background: Isoflavones from soybeans may provide some beneficial impacts on postmenopausal health. The
purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and
genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai
women.
Methods: We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai
women. In the first phase, each subject randomly received either 2 soy extract capsules (containing daidzin :
genistin = 7.79 : 22.57 mg), or soy beverage prepared from 15 g of soy flour (containing daidzin : genistin = 9.27
: 10.51 mg). In the second phase, the subjects received an alternative preparation in the same manner after a
washout period of at least 1 week. Blood samples were collected immediately before and at 0.5, 1, 2, 4, 6, 8, 10,
12, 24 and 32 h after administration of the soy preparation in each phase. Plasma daidzein and genistein
concentrations were determined by using high performance liquid chromatography (HPLC). The pharmacokinetic
parameters of daidzein and genistein, i.e. maximal plasma concentration (Cmax), time to maximal plasma
concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (t1/2), were estimated
using the TopFit version 2.0 software with noncompartmental model analysis.
Results: There were no significant differences in the mean values of Cmax/dose, AUC0–32/dose, AUC0-∝ /dose,
Tmax, and t1/2 of genistein between both preparations. For pharmacokinetic parameters of daidzein, the mean
values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations. Nonetheless, the mean
AUC0–32/dose and AUC0-∝ /dose after administration of soy extract capsules were slightly (but significantly, p <
0.05) higher than those of soy beverage.
Conclusion: The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following
a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules,
whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were
comparable. The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the
dose, Tmax and t1/2, were not different between both soy preparations.
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Background
Menopause is associated with estrogen deficiency and its
accompanying symptoms such as accelerated bone loss
and atherosclerosis. Hormone replacement therapy
(HRT) has traditionally been used for treatment of meno-
pausal disorders. Estrogen helps to maintain bone den-
sity, relieve menopausal symptoms, as well as influence
emotional state [1]. Estrogen replacement therapy after
menopause therefore improves the health and quality of
life for women. However, the Women's Health Initiative
(WHI) randomized controlled trial has recently found
that although estrogen-alone hormone therapy reduces
the risk of hip and other fractures in healthy postmeno-
pausal women with prior hysterectomy, it significantly
increases the risk of stroke (but has no significant effect on
the risk of coronary heart disease, breast or colorectal can-
cer) [2]. In addition, long-term estrogen replacement ther-
apy in postmenopausal women who have a uterus might
has the disadvantage of being tissue agonists for endome-
trial tissue, which increases the incidence of endometrial
cancer [3]. Although adding progestin to estrogen can be
used to prevent the development of endometrial cancer,
this combination may cause some unwanted side effects,
i.e. breast cancer, venous thromboembolism, stroke and
coronary heart disease [3]. Thus, alternative therapies,
which include natural products such as phytoestrogens
and herbs, offer attractive options because they may pro-
tect against breast and endometrial cancer, have fewer side
effects and still provide health benefits [4].
The most common forms of phytoestrogens are the isofla-
vones. Among the food consumed by humans, soybeans
contain the highest concentration of isoflavones. Isofla-
vones have a chemical structure resembling that of estro-
diol-17β , the most potent mammalian estrogen. The
major isoflavones, namely, genistein and daidzein, have
several features in common with estradiol-17β , including
an aromatic A ring with hydroxyl group in the same plane
at a distance similar to that in estradiol (Figure 1) [5].
Indeed, isoflavones appear to have both estrogenic and
antiestrogenic effects, like selective estrogen receptor
modulators (SERMs), depending on the target tissue [6].
Therefore, rather than classifying soy isoflavones as "estro-
gens", they should be judged more correctly as natural
SERMs. Reproductive cells, especially those of the breast
and uterus, are rich in estrogen receptor α  (ERα ), whereas
other cells (such as those in the bone) have greater
amounts of estrogen receptor β  (ERβ ) than ERα . This dif-
ferential distribution of the two types of estrogen recep-
tors, and the greater affinity of the isoflavones for ERβ  in
relation to ERα , suggests that the isoflavones have differ-
ent effects in different tissue [7].
Despite the beneficial effects of isoflavones on postmeno-
pausal health are still controversial, there are some
researches, including epidemiological studies, suggest
that isoflavones may help to alleviate postmenopausal
symptoms and protect against chronic diseases such as
hormone-dependent cancer (e.g. breast and endometrial
cancer), cardiovascular diseases and osteoporosis [8-11].
Thus, in terms of both health promotion and chronic dis-
ease prevention, the potential public health impact of
daily soy consumption could be important, especially in
postmenopausal women.
Although many commercial soy capsules containing iso-
flavone extract are now available in many Western coun-
tries, soybeans and soy food (such as tofu, soy flour, soy
milk, etc.), which provide the main sources of isoflavones,
are consumed in significant amounts in Asian countries
because they are inexpensive and high in quality protein.
The purpose of this trial was to compare the pharmacoki-
netics of plasma isoflavones, daidzein and genistein, in
postmenopausal Thai women after a single dose of orally
administered commercial soy extract capsules and soy
beverage.
Methods
Study design
This study was a single dose, randomized two-phase cross-
over study with a washout period of at least one week. It
was approved by the Medical Ethics Committee of the Fac-
ulty of Medicine, Chiang Mai University and was in com-
pliance with the Helsinki Declaration.
Subjects
A total of 12 postmenopausal Thai women, who ranged in
age from 46–61 years (average 52.83 ± 3.88 years), partic-
ipated in this study. Their mean weight and height was
52.23 ± 6.38 kg and 1.54 ± 0.06 cm, respectively. The
body mass index (BMI) of each subject was within 18–24
kg/m2 (22.06 ± 1.83 kg/m2). Their serum follicle-stimulat-
ing hormone concentrations were more than 20 IU/l and
the average level was 69.60 ± 31.21 IU/l. All had to be in
good health on the basis of medical history and physical
examination. Routine blood tests including complete
blood count (CBC) with differential, blood urea nitrogen
(BUN), creatinine (Cr) and liver function test (LFT) had to
be within the normal limit. Subjects had to give both ver-
bal and written information regarding the study. Signed
informed consent was obtained prior to entry. Exclusion
criteria included subjects with known premenopausal sta-
tus (<12 months since the last spontaneous menstrual
bleeding and a serum follicle-stimulating hormone con-
centration ≤  20 IU/l) as well as those with a known history
of chronic renal, liver, pulmonary or cardiovascular dis-
eases, recent cigarette smoking, substance abuse or addic-
tion, use of antibiotics within the previous 6 weeks,
consumption of more than 2 alcoholic drinks/day, regularBMC Clinical Pharmacology 2005, 5:2 http://www.biomedcentral.com/1472-6904/5/2
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use (more than 1 dose/week) of over-the-counter or pre-
scribed medications, and malignancy.
Isoflavone preparations
The isoflavone preparations used in this study were com-
mercial soy extract capsules and soy beverage. Soy extract
capsules were purchased from Canada, whereas, the soy
beverage was prepared from mixing 15 g of commercial
soy flour (Doi Khum®, Chiang Mai, Thailand, lot no.
19GODE) with 300 ml of hot water. The concentration of
isoflavones in each preparation was measured as agly-
cones (daidzein and genistein) and β -glycoside conju-
gates of isoflavones (daidzin and genistin) that were
analyzed by high performance liquid chromatography
(HPLC) as described below.
Quantification of isoflavones in soy preparations
Two soy preparations, soy flour and soy extract capsules,
were chosen as isoflavone sources. The sample extractions
and concentration determinations were modified from
the method described by Nakamura et al. [12]. Two hun-
dred mg of soy flour or 300 mg of powder from the soy
capsule (1 capsule) was placed in a centrifuge tube. Ten
ml of 80% methanol in water was added to the centri-
fuged tubes, and sonicated for 30 min. Isoflavonoids were
extracted for 24 h at an ambient temperature. One ml of
the mixture was centrifuged, and 10 µl of clear superna-
tant was diluted with mobile phase (100 times for soy
flour and 400 times for soy extract capsule) and spiked
with 20 µl of internal standard (IS, 100,000 ng/ml fluores-
cein and 50,000 ng/ml chloramphenicol for quantifica-
tion of aglycones and β -glycosides, respectively). Five µl of
the mixture was injected into the HPLC system. Separa-
tion was performed isocratically at 50°C. The flow rate of
the mobile phase was maintained at 1 ml/min and the
analytes were detected by UV absorption at 259 nm. The
mobile phase for the quantification of aglycones con-
sisted of 5 mM phosphoric acid in methanol/acetonitrile
Structures of isoflavones Figure 1
Structures of isoflavones.
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(100:85, v/v), whereas, that for quantification of β -glyco-
side conjugates comprised 5 mM phosphoric acid in
methanol/acetonitrile (80:20, v/v). The Isoflavone con-
tents of unknown samples were determined by using a
calibration curve of the peak height ratios of isoflavones
and IS versus respective isoflavone concentrations with
the use of linear regression. All samples were analyzed
within the same day, in which intraday assay validation
was performed.
Dosage and drug administration
Subjects were admitted to the Clinical Pharmacology Unit
of the Faculty of Medicine, Chiang Mai University at 6:30
a.m. after an overnight fast of at least 8 h. They were ran-
domized to receive either 2 soy extract capsules with 300
ml of water, or 300 ml of soy beverage at 7:00 a.m. They
remained upright and fasted for 2 h after soy product
administration. Water and lunch were served at 2 h and 4
h, respectively after dosing. Blood samples were collected
at different time points (see below). After the blood sam-
ple collection at 12 h postdose, the subjects were dis-
charged from the Clinical Pharmacology Unit and asked
to come back again on the next day to give blood samples
at 24 and 32 h postdose. While waiting for blood sample
collections, the subjects were allowed to perform all of
their daily activities, except moderate to high degrees of
exercises. After a washout period of at least 1 week, the
subjects received the alternative preparation and the
blood samples were collected in the same manner. Identi-
cal food and fluid were served during the 2 study periods.
The subjects were required to refrain from drinking caf-
feine containing beverages and alcohol, and instructed to
consume no soy products (except those given in this
study) from the time of screening until the end of the
research.
Blood sample collection
Venous blood samples (7 ml/each) for determination of
soy isoflavones were collected predose and then exactly
0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 h after administration.
Samples were obtained from the forearm by venipuncture
through an indwelling intravenous catheter (BD Insyte®)
and collected in a heparinized vacutainer (BD Insyte®).
The blood collecting tubes were centrifuged at 2,500 rpm
for 20 min and the plasma samples were separated and
frozen at -20°C until analyzed.
Determination of plasma isoflavone concentrations
The assay was modified from the solid phase extraction
procedure and HPLC technique as previously described by
Thomas et al [13]. Briefly, an aliquot (125 µl) of plasma
was transferred to a 1.5 ml plastic vial and treated with
0.25 ml of β -glucuronidase/sulfatase mixture from Helix
pomatia  (Sigma G-0876) to hydrolyze glucuronide and
sulfate conjugates of genistein and daidzein. The enzyme
mixture was made up freshly and contained 0.15 g of
ascorbic acid in 10 ml of 0.2 M acetate buffer, pH 4.0, and
500 µl of β -glucuronidase/sulfatase from Helix pomatia. To
allow for complete hydrolysis in the plasma samples, 0.75
ml of 0.2 M ammonium acetate buffer was added, and the
tubes were capped and heated overnight in a water bath
(15–18 h, 37°C). The tubes were removed from the water
bath and allowed to cool to room temperature. After enzy-
matic hydrolysis, plasma samples were spiked with 5 µl of
internal standard (IS, 100,000 ng/ml fluorescein in 80%
methanol). After vortex mixing for 30 sec and centrifuga-
tion at 13,000 rpm for 5 min, sample purification was per-
formed by using a solid phase extraction cartridge placed
in the vacuum box. The cartridges were preconditioned
with 2.50 ml each of methanol, water and 175 mM phos-
phate buffer, respectively. The samples were loaded into
the cartridges and allowed to flow freely, then the car-
tridges were washed with 0.1 ml of 20% methanol in
water, 0.1 ml of 175 mM phosphate buffer and 0.1 ml of
20% methanol in water, consecutively. After drying the
cartridge by slow suction, isoflavones and IS were eluted
with 2.0 ml of 20% methanol in ethyl acetate. The eluents
were dried by a SpeedVac concentrator. The residues were
dissolved in 50 µl of the mobile phase, and 10 µl of sam-
ples were injected into a HPLC system. The mobile phase
consisted of 4 mM perchloric acid in methanol/ace-
tonitrile (115:85, v/v). The flow rate was maintained at 1
ml/min and the analytes were detected by UV absorption
at 259 nm, and the column was maintained at 40°C. The
retention time for daidzein and genistein was 7.699 and
13.031 minutes, respectively. The lower limit of quantita-
tion was 5 ng/ml. Plasma concentrations of daidzein and
genistein were determined using a calibration curve and
linear regression of the seven known isoflavone concen-
trations versus the peak height ratios of isoflavones and IS.
The %CV of intraday precision for plasma daidzein con-
centrations ranged from 0.85–9.45%, whereas, the %CV
of interday ranged from 3.90–9.96%. The %CV of intra-
day and interday precision for plasma genistein concen-
trations ranged from 1.29–3.65%, and 4.37–6.84%,
respectively. The %deviation in intraday and interday
assay for plasma daidzein concentrations ranged from
4.35–5.84% and -6.11–4.22%, respectively. On the other
hand, the %deviation in intraday and interday assay for
plasma genistein concentrations ranged from -5.00–
1.98% and -7.79%–1.52%, respectively.
Data analysis and statistical methods
Pharmacokinetic parameters
The maximal plasma concentration (Cmax, ng/ml) and
time to maximal plasma concentration (Tmax, h) were
obtained directly by the visual inspection of each subject's
plasma concentration-time profile. The areas under the
plasma concentration-time curve from time 0–32 (AUC0–BMC Clinical Pharmacology 2005, 5:2 http://www.biomedcentral.com/1472-6904/5/2
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32, ng.h/ml) and 0-∝  (AUC0-∞ , ng.h/ml) as well as half-life
(t1/2, h) were determined by non-compartmental analysis.
The slope of the terminal log-linear portion of the concen-
tration-time profile was determined by least-squares
regression analysis and used as the elimination rate con-
stant (Ke). The elimination t1/2 was calculated as 0.693/Ke.
The AUC from time zero to the last quantifiable point
(AUC0–32) was calculated using the trapezoidal rule.
Extrapolated AUC from time t to infinity (AUCt-∞ ) was
determined as Ct/Ke. Total AUC was the sum of AUC0–32+
AUC32-∞ . In this study, the sampling time was continued
for more than 3 half-lives, therefore, the AUC0-32 was suf-
ficient to cover at least 80% of the total AUC. The calcula-
tion was performed by using the TopFit software version
2.0 for personal computer.
Statistical analysis
The pharmacokinetic parameters were presented as mean
± SD. The differences between the mean values of Cmax/
dose, Tmax, t1/2, AUC0–32/dose and AUC0-∝ /dose of the two
isoflavone preparations were statistically analyzed by
using the paired t-test. However, the results from the anal-
ysis were not different regardless of whether the statistical
comparison was performed by using the paired t-test (par-
ametric method) or Wilcoxon's sign rank test (non-para-
metric method).
Results
Isoflavone contents in soy preparations
The quantification of isoflavone contents demonstrated
that both soy flour and soy extract capsule preparations
contained predominantly daidzin and genistin (the form
of β -glycoside conjugates), whereas, aglycones were rarely
found and isoflavones in other forms were not measured.
Isoflavone contents in both soy preparations are shown in
Table 1.
Pharmacokinetics of daidzein and genistein in healthy 
postmenopausal Thai women
The Mean plasma daidzein and genistein concentration-
time curves after a single dose of both orally administered
soy preparations are shown in Figure 2, 3. The individual
and mean pharmacokinetic parameters of daidzein and
Table 1: Isoflavone contents in soy preparations used in this 
study.
Daidzin Genistin Total1
Soy flour
Mg/g 0.62 ± 0.005 0.70 ± 0.01 1.32 ± 0.01
%4 7 5 3 1 0 0
Soy extract capsule
Mg/capsule 3.90 ± 0.04 11.29 ± 0.17 15.18 ± 0.21
%2 6 7 4 1 0 0
1Summation of daidzin and genistin contents.
Mean plasma daidzein concentration-time curves after a sin- gle dose of orally administered soy beverage and soy extract  capsules Figure 2
Mean plasma daidzein concentration-time curves after a sin-
gle dose of orally administered soy beverage and soy extract 
capsules.
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Mean plasma genistein concentration-time curves after a sin-
gle dose of orally administered soy beverage and soy extract 
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genistein following oral administration of soy beverage
and soy extract capsules are shown in Tables 2, 3.
The mean plasma daidzein concentration-time curve after
a single dose of both orally administered soy preparations
revealed a biphasic pattern. The first peak of plasma daid-
zein concentration was reached approximately 1 h after
ingestion of both preparations, whereas, the second peak
attained higher plasma concentrations at 5.92 ± 2.43 h for
soy beverage, and 6.25 ± 2.26 h for soy extract capsules.
Table 2: Individual and mean pharmacokinetic parameters of daidzein following a single dose of orally administered soy beverage (B) 
and soy extract capsules (C).
Subj 
No.
Cmax (ng/ml) Cmax/Dose1 AUC0–32 (ng.h/ml) AUC0–32/Dose1 AUC0-∝  (ng.h/ml) AUC0-∝ /Dose1 Tmax (h) t1/2 (h)
BCB C B C BC B C BC B C B C
1 67.42 60.73 7.27 7.80 354.62 650.40 38.25 83.49 496.21 722.51 53.53 92.75 6 6 6.06 8.04
2 142.17 56.33 15.34 7.23 1142.38 931.84 123.23 119.62 1206.09 1024.24 130.11 131.48 6 1 6.74 6.02
3 64.95 76.70 7.01 9.85 1118.40 1117.20 120.65 143.41 1704.60 1171.78 183.88 150.42 8 6 19.80 6.85
4 132.30 124.43 14.27 15.97 1336.29 1356.49 144.15 174.13 1402.26 1427.11 151.27 183.20 6 6 6.70 6.91
5 77.66 93.20 8.38 11.96 1293.52 1251.35 139.54 160.64 1483.69 1561.72 160.05 200.48 8 10 9.94 10.50
6 105.65 142.82 11.40 18.33 1409.24 1378.43 152.02 176.95 1533.26 1450.55 165.40 186.21 10 6 6.21 6.86
7 160.86 125.37 17.35 16.09 1576.65 1669.28 170.08 214.28 1761.36 1721.18 190.01 220.95 4 6 8.48 5.97
8 102.77 74.08 11.09 9.51 1158.07 1090.36 124.93 139.97 1227.07 1149.04 132.37 147.50 6 6 6.85 6.76
9 45.34 105.77 4.89 13.58 300.89 849.39 32.46 109.04 340.35 876.40 36.72 112.50 4 6 3.46 4.40
10 52.98 84.74 5.72 10.88 401.82 579.95 43.35 74.45 533.03 761.42 57.50 97.74 1 6 4.82 4.38
11 99.98 87.38 10.79 11.22 1291.80 1546.66 139.35 198.54 1455.80 1705.46 157.04 218.93 8 10 6.59 7.63
12 103.60 120.64 11.18 15.49 578.60 909.87 62.42 116.80 665.06 971.69 71.74 124.74 4 6 6.49 5.71
Mean 96.31 96.02ND 10.39 12.33 996.86 1110.94ND 107.54 142.61* 1150.73 1211.93ND 124.14 155.57* 5.92 6.25 7.68 6.67
SD 36.18 27.71 3.90 3.56 455.69 342.26 49.16 43.94 504.94 354.46 54.47 45.50 2.43 2.26 4.14 1.65
1Pharmacokinetic parameters adjusted for oral administered dose. ND = statistical analysis was not performed due to differences in oral 
administered doses between both preparations, *Statistical significance (p < 0.05) compared to corresponding values of soy extract capsules.
Table 3: Individual and mean pharmacokinetic parameters of genistein following a single dose of orally administered soy beverage (B) 
and soy extract capsules (C).
Subj 
No.
Cmax (ng/ml) Cmax/Dose1 AUC0–32 (ng.h/ml) AUC0–32/Dose1 AUC0-∝  (ng.h/ml) AUC0-∝ /Dose1 Tmax (h) t1/2 (h)
B C B CB C BC B C BC B C B C
1 90.41 151.49 8.60 6.71 954.82 1950.40 90.85 86.42 1040.69 2248.09 99.02 99.61 6 6 8.46 9.92
2 68.08 124.90 6.48 5.53 693.31 1821.17 65.97 80.69 739.89 1941.50 70.40 86.02 1 8 7.62 7.42
3 149.53 301.34 14.23 13.35 1801.34 4392.34 171.39 194.61 1989.66 5048.92 189.31 223.70 8 8 8.25 9.37
4 212.94 516.77 20.26 22.90 1979.53 5541.88 188.35 245.54 2140.25 6175.55 203.64 273.62 6 6 8.10 8.93
5 96.95 220.38 9.22 9.76 1281.58 2478.42 121.94 109.81 1423.11 3072.33 135.41 136.12 8 10 9.73 12.40
6 96.57 301.62 9.19 13.36 1277.75 2776.28 121.57 123.01 1483.87 2972.50 141.19 131.70 10 6 10.10 7.74
7 223.77 371.31 21.29 16.45 3184.25 5260.83 302.97 233.09 4022.02 6003.94 382.69 266.01 4 8 12.60 9.58
8 110.60 193.01 10.52 8.55 948.75 2217.44 90.27 98.25 998.31 2370.24 94.99 105.02 6 6 5.07 8.41
9 54.86 183.88 5.22 8.15 425.80 1481.47 40.51 65.64 527.69 1500.60 50.21 66.49 4 6 4.41 4.80
10 69.95 214.54 6.66 9.51 773.90 1856.73 73.63 82.27 789.07 1940.05 75.08 85.96 6 6 5.34 6.63
11 105.13 217.57 10.00 9.64 1128.81 3121.71 107.40 138.31 1177.74 3208.73 112.06 142.17 6 8 6.32 5.27
12 117.61 345.31 11.19 15.30 871.60 2591.36 82.93 114.81 914.46 2631.99 87.01 116.61 4 6 5.35 5.05
Mean 116.37 261.84ND 11.07 11.60 1276.79 2957.50ND 121.48 131.04 1437.23 3259.54ND 136.75 144.42 5.75 7.00 7.61 7.96
SD 53.80 110.68 5.12 4.90 746.04 1372.13 70.98 60.79 949.02 1599.34 90.30 70.86 2.34 1.35 2.44 2.28
1Pharmacokinetic parameters adjusted for oral administered dose. ND = statistical analysis was not performed due to differences in oral 
administered doses between both preparations.BMC Clinical Pharmacology 2005, 5:2 http://www.biomedcentral.com/1472-6904/5/2
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The mean maximal plasma daidzein concentrations
(Cmax) were 96.31 ± 36.18 ng/ml and 96.02 ± 27.71 ng/ml
for soy beverage and soy extract capsules, respectively.
Pharmacokinetic analysis of the plasma concentration-
time curves showed that the elimination t1/2 was 7.68 ±
4.14 h for soy beverage and 6.67 ± 1.65 h for soy extract
capsules. The AUC0–32 was 996.86 ± 455.69 and 1110.94
± 342.26 ng.h/ml for soy beverage and soy extract cap-
sules, respectively, whereas, the AUC0-∝  was 1,150.73 ±
504.94 ng.h/ml for soy beverage and 1,211 ± 354.46 ng.h/
ml for soy extract capsules.
The mean plasma genistein concentration-time curve after
a single dose of both orally administered soy preparations
also demonstrated a biphasic pattern, but the first peak of
plasma genistein concentration after ingestion of soy
extract capsules was less evident. The mean Tmax for the
second peak of plasma concentration was 5.75 ± 2.34 h
for soy beverage and 7.00 ± 1.35 h for soy extract capsules.
The mean Cmax was 116.37 ± 53.80 ng/ml for soy beverage
and 261.84 ± 110.68 ng/ml for soy extract capsules. Phar-
macokinetic analysis of the plasma concentration-time
curves showed the elimination t1/2 of 7.61 ± 2.44 h for soy
beverage and 7.96 ± 2.28 h for soy extract capsules. The
AUC0–32 was 1276.79 ± 746.04 and 2957.50 ± 1372.13
ng.h/ml for soy beverage and soy extract capsules,
respectively, whereas, the AUC0-∝  was 1,437.23 ± 949.02
ng.h/ml for soy beverage and 3,259.54 ± 1,599.34 ng.h/
ml for soy extract capsules.
After oral administration of both soy preparations, the
pharmacokinetic parameters of daidzein were statistically
compared, and the mean values of Cmax/dose, Tmax, and t1/
2 did not significantly differ between both preparations.
Nonetheless, the mean values of AUC0–32/dose and AUC0-
∝ /dose after administration of soy extract capsules were
slightly (but significantly, p < 0.05) higher than those
after soy beverage intake (Table 2). For pharmacokinetic
parameters of genistein, there were no significant differ-
ences in the mean values of Cmax/dose, AUC0–32/dose,
AUC0-∝ /dose, Tmax, and t1/2 between both preparations
(Table 3).
Discussion
In this study, the pharmacokinetics of plasma daidzein
and genistein were evaluated in 12 postmenopausal Thai
women after a single dose of orally administered soy bev-
erage and soy extract capsules. These women were
enrolled from a pool of volunteers after they had been
screened for medical history, BMI, serum follicle-stimulat-
ing hormone concentration and blood tests. Since the
design of this study was similar to that of the
bioequivalence testing, 12 subjects were enrolled accord-
ing to the minimum number of subjects stipulated by the
Canadian and European guidelines for bioequivalence
testing.
The soy extract product available in Thailand was not
selected as the study preparation because only minimum
isoflavone content was labeled without any details about
the proportion of daidzin and genistin content. The Cana-
dian soy extract preparation was used as an alternative
because the exact total of isoflavone content (18.2 mg/
capsule) as well as daidzin and genistin content (9.1 mg/
capsule, each) were declared. Nonetheless, our quantifica-
tion of isoflavones in this preparation revealed that the
amount of daidzin and genistin in each capsule was 3.90
± 0.04 and 11.29 ± 0.17, respectively. Therefore, the orally
administered dose in this study was calculated according
to our quantification, but not by the amount declared.
Initially, we tried to measure the total isoflavone contents
in each preparation by using the acid hydrolysis method
[14,15]. Briefly, either 1 g of soy flour or powder from the
soy extract capsules was dispersed in a mixture of 10 ml of
10 M HCl and 40 ml of 96% ethanol (containing 0.05%
butylated hydroxy toluene, BHT) followed by refluxing at
100°C for 2 h. The mixture was cooled to room
temperature and the ethanol lost during the refluxing was
replaced. One ml of this mixture was centrifuged. Ten µl
of clear supernatant was diluted 100 times and deter-
mined by the HPLC method. The principle of this assay is
to hydrolyze β -glycoside conjugates of isoflavones to agly-
cones, and the detection of total aglycones reflects the
total isoflavones. Unfortunately, we failed to measure
total isoflavones as aglycones after acid hydrolysis. The
recovery of daidzein and genistein was very low (approxi-
mately 20–30%) as compared to the other published
data, even though we had tried to vary many factors such
as the concentration of HCl, duration of refluxing time,
temperature during reflux, amount of BHT added, etc.
However, since isoflavones are present predominantly as
β -glycoside conjugates (e.g. daidzin and genistin) in most
commercially available soy products such as soybean or
soy flour (with the exception of fermented soy products)
[14], we used a specific HPLC condition for measuring
daidzin and genistin, and another condition for measur-
ing aglycones (daidzein and genistein) without acid
hydrolysis. Isoflavones in other forms (malonyl glycoside
and acetyl glycoside conjugates) were not determined
because their commercial standards were not available.
Glycitein and its derivatives were also not determined,
due to a much smaller amount found in soybeans [16].
Since both soy preparations consist of different propor-
tions of daidzin : genistin (approximately 1:1 for soy
flour, 1:3 for soy extract capsules), the appropriate
amount of daidzin content in each preparation was
therefore considered first for pharmacokinetic compari-BMC Clinical Pharmacology 2005, 5:2 http://www.biomedcentral.com/1472-6904/5/2
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son. In this study, each volunteer was assigned to receive
2 capsules of soy extract (daidzin : genistin = 7.79 : 22.57
mg) to compare with soy beverage prepared from 15 g of
soy flour (9.27 : 10.51 mg). These dosages caused an
approximately equal amount of daidzin between the two
preparations, whereas, the genistin content in soy extract
capsules was approximately two-fold higher than that of
soy beverage. The oral administration of these dosages
resulted in the plasma concentrations of daidzein and
genistein being high enough and convenient for measure-
ment by the HPLC method. In addition, preparing soy
beverage from 15 g of soy flour in 300 ml of water was
practical and created an acceptable concentration for
consumption.
From previous studies, the bioavailability of isoflavones
was investigated and compared among various soy food
and beverages. So far, there has been no study that com-
pares bioavailability of isoflavones from soy extract versus
natural soy food or beverages. Our purpose was to inves-
tigate pharmacokinetics of daidzein and genistein after
ingestion of soy beverage compared to soy extract capsules
in postmenopausal Thai women. Daidzein and genistein
contents in soy food can vary and depend on the raw
material and processing conditions used to produce a par-
ticular food product. Furthermore, in each type of soy
food, there are different forms of isoflavones in differing
amounts. However, based on the equivalent dose of iso-
flavones, the administration of different soy food has
shown no difference in isoflavone bioavailability [17]. In
our study, the bioavailability, adjusted for dosage
(determined by AUC0–32/dose and AUC0-∝ /dose) of genis-
tein after ingestion of both soy preparations, was not sig-
nificantly different. In contrast, the bioavailability of
daidzein following ingestion of soy extract capsules was
significantly greater than that following ingestion of soy
beverage. This might be the result of at least 2 possibilities.
Firstly, the food matrix of soy flour may alter the
bioavailability of daidzein. Dietary factors such as fiber
and carbohydrate have been associated with differences in
the metabolism of daidzein to equol [18-20]. Urinary
recovery of equol is higher following the ingestion of tem-
peh when compared with homogeneous soymilk and tex-
tured vegetable protein. This suggests that the
combination of a food matrix might protect daidzein
from degradation until it reaches the large intestine where
it can be metabolized to equol by the microflora [20]. Sec-
ondly, in this study, we only determined the isoflavone
contents in both soy preparations as the forms of β -glyco-
side conjugates (daidzin and genistin) as well as aglycones
(daidzein and genistein). However, soy flour and soy
extract capsules might have contained some malonyl gly-
coside and acetyl glycoside conjugates of isoflavones,
which were not measured in this study. We postulate that
the proportions of malonyl glycoside and acetyl glycoside
conjugates of daidzein in soy extract capsules may be
greater than those in soy flour, resulting in better bioavail-
ability after these conjugates are converted and absorbed
as daidzein from the gastrointestinal tract.
The mean Tmax of daidzein and genistein from both soy
preparations in this study was shorter than the values of
8–11 h (after ingestion of β -glycoside conjugates) as
reported in previous studies [21,22]. This difference might
result from variation in age, race, uptake rates, hydrolysis
of glycosides by gut bacteria or gut wall enzymes, further
metabolism (for example glucuronides within the liver),
etc. The second peak demonstrated in the plasma concen-
tration-time curves of daidzein and genistein possibly
resulted from enterohepatic recirculation of the glucuro-
nide and sulfate conjugates of isoflavones excreted in bile
[22]. The elimination t1/2 of daidzein and genistein in this
study was comparable to the values of 6–8 h from other
studies [20-22].
It has been suggested that a daily intake of soy isoflavone
extract containing 50/50 mg of genistin and daidzin [23]
or 76 mg of isoflavones [24] can significantly decrease hot
flushes in the group treated with soy products over the
placebo. A meta-analysis of 38 clinical trials, which exam-
ined the relationship between soy protein intake and
serum lipids, have shown that the consumption of soy in
men and women is associated with a significant decrease
in serum cholesterol, LDL and triglyceride levels [25]. In a
randomized, double-blind, placebo-controlled trial,
which examined the effects of dietary soy supplements
containing 118 mg of isoflavones on the lipid profiles of
men and postmenopausal women with relatively normal
cholesterol levels, the LDL/HDL ratio decreases in the iso-
flavone treatment groups without any change in total cho-
lesterol [26]. In addition, it has been found that those
postmenopausal women with greatest phytoestrogen con-
sumption have the highest bone mineral density (BMD)
at the hip and spine. Subjects with the highest intake of
isoflavones also have significantly lower levels of serum
PTH, osteocalcin and urinary N-telopeptide [27]. Besides,
isoflavone supplementation (61.8 mg of isoflavones) for
four weeks shows potentially beneficial effects on bone
metabolism and serum lipids in perimenopausal women
in a randomized controlled trial [28]. Another trial has
demonstrated that continuous dietary intake of isofla-
vones (37.3 mg/day) for ten weeks may inhibit
postmenopausal osteoporosis [29]. Therefore, in our
opinion, the total dose of isoflavones that benefits meno-
pausal health is up to approximately 100 mg/day. Since
our study revealed that the bioavailability of genistein
from soy beverage and soy extract capsules was similar,
and the bioavailability of daidzein was slightly (although
statistically significant) lower than that of soy extract cap-
sules, the amount of soy beverage, which provides the iso-BMC Clinical Pharmacology 2005, 5:2 http://www.biomedcentral.com/1472-6904/5/2
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flavone bioavailability equivalent to soy isoflavone
capsules containing 50/50 mg of daidzein and genistein,
should be equal to approximately 5 cups/day (15 g of soy
flour/cup). If one consumes other soy food or prepares a
soy beverage in a higher concentration, the daily volume
of consumption would be reduced. This inexpensive soy
beverage is an appropriate alternative food supplementa-
tion compared to the more expensive soy extract capsules
and HRT for postmenopausal Thai women, and is in line
with Thailand's present socioeconomic status. However,
the different proportion of daidzein and genistein in vari-
ous soy preparations might affect beneficial outcomes for
postmenopausal women. In this aspect, clinical studies
should be investigated further.
Conclusion
The bioavailability of daidzein, which was adjusted for
the administered dose (AUC/dose) following a single oral
administration of soy beverage, was slightly (but signifi-
cantly) less than that of soy extract capsules, whereas, that
of genistein from both soy preparations was comparable.
There was also no difference in other pharmacokinetic
parameters of daidzein and genistein, including Cmax
adjusted for dose, Tmax  and t1/2  between both soy
preparations.
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